PCDH8

Summary

PCDH8 (protocadherin 8, HGNC:8660) is a protein-coding gene on chromosome 13q14.3, encoding Protocadherin-8 (O95206). Calcium-dependent cell-adhesion protein.

This gene belongs to the protocadherin gene family, a subfamily of the cadherin superfamily. The gene encodes an integral membrane protein that is thought to function in cell adhesion in a CNS-specific manner. Unlike classical cadherins, which are generally encoded by 15-17 exons, this gene includes only 3 exons. Notable is the large first exon encoding the extracellular region, including 6 cadherin domains and a transmembrane region. Alternative splicing yields isoforms with unique cytoplasmic tails.

Source: NCBI Gene 5100 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 177 total — 1 pathogenic
• MANE Select transcript: NM_002590

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8660
Approved symbol	PCDH8
Name	protocadherin 8
Location	13q14.3
Locus type	gene with protein product
Status	Approved
Aliases	PAPC, ARCADLIN
Ensembl gene	ENSG00000136099
Ensembl biotype	protein_coding
OMIM	603580
Entrez	5100

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 retained_intron

ENST00000338862, ENST00000377942, ENST00000613548

RefSeq mRNA: 2 — MANE Select: NM_002590 NM_002590, NM_032949

CCDS: CCDS9438, CCDS9439

Canonical transcript exons

ENST00000377942 — 3 exons

Exon	Start	End
ENSE00000836988	52845425	52845632
ENSE00001475589	52845806	52848640
ENSE00001932872	52842889	52844933

Expression profiles

Bgee: expression breadth ubiquitous, 149 present calls, max score 97.40.

FANTOM5 (CAGE): breadth broad, TPM avg 3.0570 / max 147.3356, expressed in 315 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
137433	3.0570	315

Top tissues by expression

274 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 23	UBERON:0013554	97.40	gold quality
frontal pole	UBERON:0002795	92.15	gold quality
endothelial cell	CL:0000115	91.85	gold quality
middle temporal gyrus	UBERON:0002771	91.40	gold quality
Brodmann (1909) area 10	UBERON:0013541	89.95	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	88.66	gold quality
primary visual cortex	UBERON:0002436	88.54	gold quality
Brodmann (1909) area 9	UBERON:0013540	87.55	gold quality
superior frontal gyrus	UBERON:0002661	87.43	gold quality
nucleus accumbens	UBERON:0001882	86.90	gold quality
prefrontal cortex	UBERON:0000451	86.78	gold quality
frontal cortex	UBERON:0001870	86.44	gold quality
neocortex	UBERON:0001950	86.25	gold quality
cingulate cortex	UBERON:0003027	86.25	gold quality
anterior cingulate cortex	UBERON:0009835	86.19	gold quality
cerebral cortex	UBERON:0000956	86.10	gold quality
occipital lobe	UBERON:0002021	85.80	gold quality
caudate nucleus	UBERON:0001873	85.31	gold quality
right frontal lobe	UBERON:0002810	84.98	gold quality
telencephalon	UBERON:0001893	84.46	gold quality
orbitofrontal cortex	UBERON:0004167	84.07	gold quality
parietal lobe	UBERON:0001872	83.82	gold quality
Ammon’s horn	UBERON:0001954	83.52	gold quality
entorhinal cortex	UBERON:0002728	83.37	gold quality
postcentral gyrus	UBERON:0002581	83.30	gold quality
ganglionic eminence	UBERON:0004023	83.23	gold quality
dorsal root ganglion	UBERON:0000044	82.63	gold quality
CA1 field of hippocampus	UBERON:0003881	82.63	gold quality
Brodmann (1909) area 46	UBERON:0006483	82.12	gold quality
forebrain	UBERON:0001890	81.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.12

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MESP2, STAT3

miRNA regulators (miRDB)

98 targeting PCDH8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-98-3P	100.00	74.08	3907
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-1271-5P	99.91	71.99	1972

Literature-anchored findings (GeneRIF, showing 15)

• These results suggest that any contribution of PCDH8 polymorphisms to schizophrenia susceptibility is likely to be weak, although the existence of rare variations of stronger effect cannot be excluded. (PMID:12884975)
• Loss of PCDH8 promotes oncogenesis in epithelial human cancers by disrupting cell-cell communication dedicated to tissue organization and repression of mitogenic signaling. (PMID:18408767)
• Frequently inactivation by promoter methylation of Protocadherin8 is associated with nasopharyngeal carcinoma. (PMID:22273848)
• Loss of the PCDH8 gene is one of the probable causes of psychomotor delay in RB1-deleted patients. (PMID:22909775)
• study demonstrates the epigenetic inactivation of PCDH8 by promoter methylation and its tumor suppressor function in gastric cancer (PMID:22941331)
• PCDH8 methylation may be a useful biomarker to predict the progression of clear cell renal cell carcinoma. (PMID:25416427)
• Promoter methylation of protocadherin8 is a frequent event in prostate cancer, and might be used as an independent prognostic factor for biochemical recurrence-free survival in patients with prostate cancer. (PMID:25486497)
• PCDH8 methylation may be associated with tumor progression and poor prognosis in non-muscle invasive bladder cancer. (PMID:25927589)
• The methylation of PCDH8 in serum is a potential predictive marker for prostate cancer patients with low Gleason score. (PMID:29026066)
• Protocadherin-8 might be considered as a candidate tumor suppressor and play a crucial role in the progression of Ovarian cancer. (PMID:29324532)
• Study showed that high expression of PCDH8 was significantly correlated with poorer prognosis in gastric cancer (GC). Its ectopic expression in GC cells promoted invasion, migration and, metastasis; on the contrary, its knockdown inhibited invasion and migration of GC cell lines through LAMC2 regulation. (PMID:29325230)
• Serum downregulated miR-940 may serve as a reliable diagnostic and prognostic biomarker in breast cancer patients. (PMID:29865037)
• Protocadherin 8 (PCDH8) Inhibits Proliferation, Migration, Invasion, and Angiogenesis in Esophageal Squamous Cell Carcinoma. (PMID:32330123)
• PCDH8 participates in the growth process of colorectal cancer cells by regulating the AKT/GSK3beta/beta-catenin signaling pathway. (PMID:35907345)
• PCDH8 is a novel prognostic biomarker in thyroid cancer and promotes cell proliferation and viability. (PMID:38368303)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	PCDH8	ENSDARG00000102185
mus_musculus	Pcdh8	ENSMUSG00000036422
rattus_norvegicus	Pcdh8	ENSRNOG00000013101

Paralogs (61): PCDHB4 (ENSG00000081818), PCDHA6 (ENSG00000081842), PCDHGA2 (ENSG00000081853), PCDHB2 (ENSG00000112852), PCDHB3 (ENSG00000113205), PCDHB5 (ENSG00000113209), PCDHB6 (ENSG00000113211), PCDHB7 (ENSG00000113212), PCDHB15 (ENSG00000113248), PCDH12 (ENSG00000113555), PCDH17 (ENSG00000118946), PCDHB8 (ENSG00000120322), PCDHB10 (ENSG00000120324), PCDHB14 (ENSG00000120327), PCDHB12 (ENSG00000120328), PCDH10 (ENSG00000138650), PCDH15 (ENSG00000150275), PCDH19 (ENSG00000165194), CDH16 (ENSG00000166589), PCDHB1 (ENSG00000171815), PCDHB9 (ENSG00000177839), PCDHB13 (ENSG00000187372), CDHR4 (ENSG00000187492), PCDH18 (ENSG00000189184), PCDHB11 (ENSG00000197479), PCDHGA1 (ENSG00000204956), PCDHA9 (ENSG00000204961), PCDHA8 (ENSG00000204962), PCDHA7 (ENSG00000204963), PCDHA5 (ENSG00000204965), PCDHA4 (ENSG00000204967), PCDHA2 (ENSG00000204969), PCDHA1 (ENSG00000204970), PCDHA13 (ENSG00000239389), PCDHGC3 (ENSG00000240184), PCDHGC5 (ENSG00000240764), PCDHGC4 (ENSG00000242419), PCDHAC2 (ENSG00000243232), PCDHAC1 (ENSG00000248383), PCDHA11 (ENSG00000249158)

Protein

Protein identifiers

Protocadherin-8 — O95206 (reviewed: O95206)

Alternative names: Arcadlin

All UniProt accessions (1): O95206

UniProt curated annotations — full annotation on UniProt →

Function. Calcium-dependent cell-adhesion protein. May play a role in activity-induced synaptic reorganization underlying long term memory. Could be involved in CDH2 internalization through TAOK2/p38 MAPK pathway. In hippocampal neurons, may play a role in the down-regulation of dendritic spines, maybe through its action on CDH2 endocytosis.

Subunit / interactions. The N-terminal extracellular domain forms homophilic interactions; these interactions activate p38 MAPK via TAOK2 and trigger endocytosis. Interacts with CDH2; this interaction may lead to CDH2 cointernalization. Interacts with CDH11. Interacts with TAOK2.

Subcellular location. Cell membrane. Cell projection. Dendrite. Presynaptic cell membrane. Postsynaptic cell membrane.

Isoforms (2)

UniProt ID	Names	Canonical?
O95206-1	1	yes
O95206-2	2

RefSeq proteins (2): NP_002581, NP_116567 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002126	Cadherin-like_dom	Domain
IPR013164	Cadherin_N	Domain
IPR015919	Cadherin-like_sf	Homologous_superfamily
IPR020894	Cadherin_CS	Conserved_site
IPR050174	Protocadherin/Cadherin-CA	Family

Pfam: PF00028, PF08266

UniProt features (57 total): strand 18, domain 6, region of interest 5, sequence variant 5, compositionally biased region 4, turn 4, glycosylation site 3, helix 3, topological domain 2, sequence conflict 2, signal peptide 1, chain 1, modified residue 1, splice variant 1, transmembrane region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6VFV	X-RAY DIFFRACTION	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95206-F1	70.23	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1054

Glycosylation sites (3): 70, 464, 616

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 198 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_EPITHELIUM_DEVELOPMENT, BENPORATH_ES_WITH_H3K27ME3, YAGI_AML_WITH_INV_16_TRANSLOCATION, STAEGE_EWING_FAMILY_TUMOR, GOBP_MORPHOGENESIS_OF_EMBRYONIC_EPITHELIUM, CEBPB_01, GOBP_CELL_CELL_SIGNALING, GOBP_CELL_CELL_ADHESION, GTGCCTT_MIR506, TCF4_Q5, GOBP_CELL_JUNCTION_ORGANIZATION, MODULE_205

GO Biological Process (9): somitogenesis (GO:0001756), homophilic cell-cell adhesion (GO:0007156), cell-cell signaling (GO:0007267), chemical synaptic transmission (GO:0007268), morphogenesis of embryonic epithelium (GO:0016331), modulation of chemical synaptic transmission (GO:0050804), cell-cell adhesion (GO:0098609), regulation of synaptic membrane adhesion (GO:0099179), cell adhesion (GO:0007155)

GO Molecular Function (2): calcium ion binding (GO:0005509), cell adhesion molecule binding (GO:0050839)

GO Cellular Component (9): plasma membrane (GO:0005886), dendrite (GO:0030425), presynaptic membrane (GO:0042734), synapse (GO:0045202), postsynaptic membrane (GO:0045211), Schaffer collateral - CA1 synapse (GO:0098685), glutamatergic synapse (GO:0098978), membrane (GO:0016020), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
synaptic membrane	2
synapse	2
cellular anatomical structure	2
anterior/posterior pattern specification	1
segmentation	1
chordate embryonic development	1
anatomical structure formation involved in morphogenesis	1
somite development	1
cell-cell adhesion	1
cell communication	1
signaling	1
anterograde trans-synaptic signaling	1
morphogenesis of an epithelium	1
embryonic morphogenesis	1
chemical synaptic transmission	1
regulation of trans-synaptic signaling	1
cell adhesion	1
regulation of cell-cell adhesion	1
regulation of synapse organization	1
synaptic membrane adhesion	1
cellular process	1
metal ion binding	1
protein binding	1
membrane	1
cell periphery	1
neuron projection	1
dendritic tree	1
presynapse	1
cell junction	1
postsynapse	1

Protein interactions and networks

STRING

1500 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PCDH8	DIPK2A	Q8NDZ4	715
PCDH8	CDH2	P19022	626
PCDH8	TAOK2	Q9UL54	582
PCDH8	PCDH11X	Q9BZA7	560
PCDH8	CDH17	Q12864	555
PCDH8	ATP7B	P35670	553
PCDH8	STX2	P32856	507
PCDH8	CALB1	P05937	425
PCDH8	PENK	P01210	424
PCDH8	SLC17A7	Q9P2U7	422
PCDH8	CFH	P08603	419
PCDH8	GAD1	Q99259	418
PCDH8	DRD2	P14416	416
PCDH8	PCDH19	Q8TAB3	416
PCDH8	IREB2	P48200	412

IntAct

7 interactions, top by confidence:

A	B	Type	Score
PCDH8	BTRC	psi-mi:“MI:0915”(physical association)	0.370
ITM2B	ILVBL	psi-mi:“MI:0914”(association)	0.350
SYNGAP1	POM121C	psi-mi:“MI:0914”(association)	0.350
HCN1	POTEF	psi-mi:“MI:0914”(association)	0.350
BRK1	PCDH8	psi-mi:“MI:0914”(association)	0.350
UBQLN4	PCDH8	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (3): PCDH8 (Affinity Capture-MS), PCDH8 (Two-hybrid), PCDH8 (Two-hybrid)

ESM2 similar proteins: A2A699, A2XVC2, A8MVW0, B0F2B4, D3ZE55, O09017, O14492, O62763, O95206, P10588, P21836, P22303, P23795, P36196, P37136, P43029, P43136, P50427, Q14003, Q29RK8, Q2QXZ2, Q2RAQ5, Q3U0S6, Q495W5, Q4ACU6, Q5T442, Q5U651, Q5ZMM1, Q62888, Q62889, Q63959, Q69ZK9, Q6UXK2, Q76KP1, Q7FA29, Q7Z4P5, Q80WV3, Q80XF7, Q869C3, Q8BQU6

Diamond homologs: A7MB46, D3ZE55, F8W3X3, O14917, O55134, O60330, O88689, O95206, Q5DRA2, Q5DRA3, Q5DRA4, Q5DRA5, Q5DRA6, Q5DRA7, Q5DRA8, Q5DRA9, Q5DRB0, Q5DRB1, Q5DRB2, Q5DRB3, Q5DRB4, Q5DRB5, Q5DRB6, Q5DRB7, Q5DRB8, Q5DRB9, Q5DRC0, Q5DRC1, Q5DRC2, Q5DRC6, Q5DRD3, Q5DRD6, Q5DRE0, Q5DRE1, Q5DRE3, Q5DRE4, Q5DRE5, Q5DRE6, Q5DRE7, Q5DRE8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

177 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	161
Likely benign	9
Benign	6

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1527762	GRCh37/hg19 13q13.1-21.31(chr13:32946120-62698217)	Pathogenic

SpliceAI

351 predictions. Top by Δscore:

Variant	Effect	Δscore
13:52845093:T:TA	donor_gain	1.0000
13:52845419:CCTCA:C	donor_loss	1.0000
13:52845420:CTCA:C	donor_loss	1.0000
13:52845421:TCA:T	donor_loss	1.0000
13:52845422:CA:C	donor_loss	1.0000
13:52845423:A:T	donor_loss	1.0000
13:52845424:CCA:C	donor_gain	1.0000
13:52845424:CCACT:C	donor_gain	1.0000
13:52845134:CAG:C	acceptor_gain	0.9900
13:52845137:C:CC	acceptor_gain	0.9900
13:52845423:A:AC	donor_gain	0.9900
13:52845423:AC:A	donor_gain	0.9900
13:52845424:C:CC	donor_gain	0.9900
13:52845424:CC:C	donor_gain	0.9900
13:52845448:T:TA	donor_gain	0.9900
13:52845628:TAGGG:T	acceptor_gain	0.9900
13:52845645:A:AC	acceptor_gain	0.9900
13:52845418:T:TA	donor_gain	0.9800
13:52845629:AGGG:A	acceptor_gain	0.9800
13:52845630:GGG:G	acceptor_gain	0.9800
13:52845631:GG:G	acceptor_gain	0.9800
13:52845632:GCTG:G	acceptor_loss	0.9800
13:52845633:C:CC	acceptor_gain	0.9800
13:52845633:CTG:C	acceptor_loss	0.9800
13:52845637:A:T	acceptor_gain	0.9800
13:52845645:A:C	acceptor_gain	0.9800
13:52845427:CT:C	donor_gain	0.9700
13:52846098:T:TA	donor_gain	0.9700
13:52845133:TCAGC:T	acceptor_loss	0.9600
13:52845135:AGCT:A	acceptor_loss	0.9600

AlphaMissense

6842 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:52846160:G:C	S759R	1.000
13:52846160:G:T	S759R	1.000
13:52846162:T:G	S759R	1.000
13:52845487:T:A	D926V	0.999
13:52845487:T:G	D926A	0.999
13:52845488:C:G	D926H	0.999
13:52845498:A:C	S922R	0.999
13:52845498:A:T	S922R	0.999
13:52845500:T:G	S922R	0.999
13:52846159:A:G	C760R	0.999
13:52846628:G:C	N603K	0.999
13:52846628:G:T	N603K	0.999
13:52846629:T:A	N603I	0.999
13:52847025:T:G	D471A	0.999
13:52847026:C:G	D471H	0.999
13:52847127:A:C	F437C	0.999
13:52847127:A:G	F437S	0.999
13:52847178:T:A	D420V	0.999
13:52847382:G:T	P352H	0.999
13:52847393:A:C	N348K	0.999
13:52847393:A:T	N348K	0.999
13:52847394:T:A	N348I	0.999
13:52847400:T:A	D346V	0.999
13:52847418:A:T	V340D	0.999
13:52847520:A:T	L306H	0.999
13:52847547:A:G	F297S	0.999
13:52847895:A:C	F181C	0.999
13:52847895:A:G	F181S	0.999
13:52848050:G:C	N129K	0.999
13:52848050:G:T	N129K	0.999

dbSNP variants (sampled 300 via entrez): RS1000022179 (13:52846341 G>A,C,T), RS1000190284 (13:52845444 G>A,T), RS1000633573 (13:52843775 T>G), RS1000663322 (13:52843342 T>C), RS1000723541 (13:52845723 A>C,G), RS1000885088 (13:52849814 G>A), RS1001196346 (13:52843756 A>T), RS1001229239 (13:52850599 T>A), RS1001261742 (13:52850172 G>C,T), RS1001730836 (13:52844199 T>A), RS1002139713 (13:52844226 C>A,T), RS1003672570 (13:52846924 A>G,T), RS1004303179 (13:52842578 G>A), RS1004330925 (13:52844631 C>A), RS1004376307 (13:52848625 G>T)

Disease associations

OMIM: gene MIM:603580 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001547_4	Immune response to anthrax vaccine	8.000000e-06
GCST001621_12	Airflow obstruction	8.000000e-07
GCST004070_10	Cerebrospinal P-tau181p levels	6.000000e-09
GCST009391_1401	Metabolite levels	2.000000e-06
GCST009391_1406	Metabolite levels	5.000000e-06
GCST009391_1788	Metabolite levels	5.000000e-06

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0004645	response to vaccine
EFO:0003892	pulmonary function measurement
EFO:0004763	p-tau measurement
EFO:0005132	5-HIAA measurement
EFO:0004468	glucose measurement
EFO:0010477	fructose measurement
EFO:0010481	galactose measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases expression, increases methylation	8
trichostatin A	affects cotreatment, increases expression	3
methylmercuric chloride	decreases expression, increases expression	2
bisphenol A	decreases methylation, increases methylation, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
Panobinostat	increases expression, affects cotreatment	2
Tetrachlorodibenzodioxin	affects cotreatment, increases expression, decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
N(4)-hydroxycytidine	decreases expression	1
arsenite	increases methylation	1
afimoxifene	increases expression	1
sodium arsenite	increases expression	1
mercuric bromide	affects cotreatment, decreases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
belinostat	increases expression	1
thifluzamide	increases expression	1
abrine	increases expression	1
pyrachlostrobin	increases expression	1
dorsomorphin	affects cotreatment, increases expression, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Amiodarone	increases expression	1
Antimycin A	increases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	affects expression	1
Cocaine	increases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.